TW279161B - - Google Patents

Info

Publication number
TW279161B
TW279161B TW083111032A TW83111032A TW279161B TW 279161 B TW279161 B TW 279161B TW 083111032 A TW083111032 A TW 083111032A TW 83111032 A TW83111032 A TW 83111032A TW 279161 B TW279161 B TW 279161B
Authority
TW
Taiwan
Prior art keywords
pct
inhibitors
sec
date
pub
Prior art date
Application number
TW083111032A
Other languages
English (en)
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Application granted granted Critical
Publication of TW279161B publication Critical patent/TW279161B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
TW083111032A 1993-11-29 1994-11-24 TW279161B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15901493A 1993-11-29 1993-11-29

Publications (1)

Publication Number Publication Date
TW279161B true TW279161B (zh) 1996-06-21

Family

ID=22570705

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083111032A TW279161B (zh) 1993-11-29 1994-11-24

Country Status (21)

Country Link
US (1) US5684017A (zh)
EP (1) EP0731791B1 (zh)
JP (1) JPH09506345A (zh)
KR (1) KR100340375B1 (zh)
CN (1) CN1044116C (zh)
AT (1) ATE177083T1 (zh)
AU (1) AU683114B2 (zh)
CA (1) CA2175458C (zh)
DE (1) DE69416859T2 (zh)
DK (1) DK0731791T3 (zh)
ES (1) ES2131297T3 (zh)
FI (1) FI109901B (zh)
GR (1) GR3029827T3 (zh)
HU (1) HU219565B (zh)
IL (1) IL111776A (zh)
NO (1) NO306211B1 (zh)
NZ (1) NZ276577A (zh)
PT (1) PT731791E (zh)
TW (1) TW279161B (zh)
WO (1) WO1995014669A1 (zh)
ZA (1) ZA949303B (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
DE19705133A1 (de) * 1997-02-11 1998-08-13 Hoechst Ag Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CN1302206A (zh) * 1997-10-17 2001-07-04 阿温蒂斯药物制品公司 喹啉衍生物的治疗用途
DE19858253A1 (de) * 1998-12-17 2000-06-21 Aventis Pharma Gmbh Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2451699A1 (en) * 2001-06-26 2003-01-09 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
SG173211A1 (en) 2001-06-26 2011-08-29 Amgen Inc Antibodies to opgl
EP1578782A4 (en) 2002-12-30 2007-09-12 Amgen Inc COSTIMULATING FACTORIAL THERAPY
KR100687522B1 (ko) * 2005-05-28 2007-02-27 한국화학연구원 2,2-디메틸-3-에스테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제
CN104447489B (zh) * 2014-12-29 2017-01-11 南京工业大学 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
AU660969B2 (en) * 1991-02-27 1995-07-13 Merrell Pharmaceuticals Inc. NMDA antagonists
ES2129794T3 (es) * 1993-11-29 1999-06-16 Merrell Pharma Inc Derivados de bencenosulfonilimina heterociclicos como inhibidores de la accion de il-1.

Also Published As

Publication number Publication date
IL111776A (en) 1999-06-20
AU1087995A (en) 1995-06-13
ATE177083T1 (de) 1999-03-15
FI962235A0 (fi) 1996-05-28
DE69416859D1 (de) 1999-04-08
EP0731791A1 (en) 1996-09-18
FI962235A (fi) 1996-05-28
IL111776A0 (en) 1995-01-24
NO306211B1 (no) 1999-10-04
NZ276577A (en) 1997-11-24
ZA949303B (en) 1995-08-07
ES2131297T3 (es) 1999-07-16
PT731791E (pt) 2000-11-30
KR960706476A (ko) 1996-12-09
DE69416859T2 (de) 1999-08-05
DK0731791T3 (da) 1999-09-27
CA2175458C (en) 1999-03-02
HUT76273A (en) 1997-07-28
FI109901B (fi) 2002-10-31
JPH09506345A (ja) 1997-06-24
WO1995014669A1 (en) 1995-06-01
KR100340375B1 (ko) 2002-11-13
AU683114B2 (en) 1997-10-30
CN1044116C (zh) 1999-07-14
HU219565B (hu) 2001-05-28
EP0731791B1 (en) 1999-03-03
NO962155D0 (no) 1996-05-28
CA2175458A1 (en) 1995-06-01
HU9601435D0 (en) 1996-07-29
NO962155L (no) 1996-05-28
GR3029827T3 (en) 1999-06-30
CN1136311A (zh) 1996-11-20
US5684017A (en) 1997-11-04

Similar Documents

Publication Publication Date Title
BR9407239A (pt) Azadioxacicloalquenos substituídos
GR3032506T3 (en) 3-aryl-2-isoxazolines as antiinflammatory agents
TW279161B (zh)
EG20693A (en) Isoxazoline compounds as antiinflammatory agents
CA2165824A1 (fr) Utilisation du modafinil pour la fabrication d'un medicament ayant un effet sur les apnees du sommeil et les troubles ventilatoires d'origine centrale
AU4623396A (en) 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
TW281671B (zh)
HUT76271A (en) Substituted aminoalkylaminopyridines, process for producing them and their use